Hyaluronidase (human recombinant)

Generic Name
Hyaluronidase (human recombinant)
Brand Names
Darzalex Faspro, Herceptin Hylecta, Hylenex, Hyqvia 5 G / 50 Ml Kit, Phesgo, Rituxan Hycela, Vyvgart Hytrulo
Drug Type
Biotech
Chemical Formula
-
CAS Number
757971-58-7
Unique Ingredient Identifier
743QUY4VD8
Background

A purified preparation of the enzyme recombinant human hyaluronidase. Hyaluronidase (human recombinant) (INN Vorhyaluronidase alfa) is produced by genetically engineered Chinese Hamster Ovary (CHO) cells containing a DNA plasmid encoding for a soluble fragment of human hyaluronidase (PH20). Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents. The action of hyaluronidase was first described in 1936, and named in 1939. Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permeability of the connective tissue. Hyaluronidase has been used in surgical settings for at least the past 60 years to improve the diffusion of local anesthetics.

Hyaluronidase was first used in prescription products in the United States on 5 May 2004.

Indication

Hyaluronidase is indicated for subcutaneous fluid administration for hydration, and increasing resorption of radiopaque agents in subcutaneous urography. Hyaluronidase is also indicated by multiple routes to increase the dispersion of other injectable drugs.

Associated Conditions
Drug Extravasation, Generalized Myasthenia Gravis, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Primary Immune Deficiency Disorders (PIDD), Primary Immunodeficiency, Secondary humoral immunodeficiency, Stage I Breast Cancer
Associated Therapies
Parenteral rehydration therapy, Improving resorption of radiopaque agents, To increase percutaneous drug absorption therapy
Clinical Trials
Related News
biospace.com
·

Johnson & Johnson submits applications in the U.S. and EU seeking approval of ...

Johnson & Johnson submits regulatory applications to FDA and EMA for DARZALEX FASPRO® as monotherapy for high-risk smoldering multiple myeloma, aiming to treat before active disease onset.

Related Clinical Trials:

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
rttnews.com
·

Johnson & Johnson Seeks Approval Of Darzalex Faspro In US, Darzalex In EU For Myeloma

Johnson & Johnson submits regulatory applications for Darzalex Faspro to the FDA and Darzalex to the EMA, based on Phase 3 AQUILA study data for high-risk smoldering multiple myeloma. If approved, Darzalex Faspro would be the first treatment option for this condition.
marketscreener.com
·

Johnson & Johnson Submits Applications in the U.S. and EU Seek Approval of DARZALEX

Johnson & Johnson submits regulatory applications to FDA and EMA for DARZALEX FASPRO and DARZALEX SC, targeting high-risk smoldering multiple myeloma. AQUILA study (NCT03301220) investigates DARZALEX FASPRO versus active monitoring in 390 patients, focusing on progression-free survival. Smoldering multiple myeloma, an asymptomatic precursor to multiple myeloma, affects 15% of newly diagnosed cases, with half of high-risk patients progressing within two years. Multiple myeloma, a blood cancer affecting plasma cells, is the second most common blood cancer globally, with an estimated 35,000 new cases and 12,000 deaths in the U.S. in 2024.

Related Clinical Trials:

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
simplywall.st
·

Three Value Stocks Priced Below Estimated Worth In November 2024

Investors focus on undervalued stocks with strong fundamentals amid market volatility. Top 10 undervalued stocks include Provident Financial Services, Proya Cosmetics, Arteche Lantegi Elkartea, Elica, Beyout Investment Group, Bangkok Genomics Innovation, BayCurrent Consulting, Redcentric, Beijing LeiKe Defense Technology, and Alnylam Pharmaceuticals. argenx SE, GFL Environmental Inc., and Dino Polska S.A. are highlighted for their significant discounts to fair value based on cash flow analysis.
myelomaresearchnews.com
·

J&J seeks new FDA approval of Darzalex Faspro myeloma combo

Johnson & Johnson seeks FDA approval for Darzalex Faspro-based quadruple regimen for newly diagnosed multiple myeloma patients not initially planning stem cell transplant. The D-VRd combo, already approved for transplant-eligible patients, showed significant benefits in the CEPHEUS trial, including higher MRD-negativity rates and reduced disease progression risk.

Related Clinical Trials:

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma
curetoday.com
·

FDA Receives Application to Review D-VRd in Multiple Myeloma Subset

Johnson & Johnson submitted an FDA application for Darzalex Faspro-based D-VRd regimen to treat newly diagnosed multiple myeloma patients ineligible for transplant, based on CEPHEUS study results showing 60.9% MRD-negativity and 43% risk reduction for progression or death.
prnewswire.com
·

Johnson & Johnson files for U.S. FDA approval of DARZALEX FASPRO®-based quadruplet

Johnson & Johnson submits sBLA to FDA for DARZALEX FASPRO® quadruplet regimen for newly diagnosed multiple myeloma patients, supported by CEPHEUS study showing 60.9% MRD-negativity and 43% reduced risk of progression or death.

Related Clinical Trials:

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma
biospace.com
·

J&J Posts Positive Phase III Results for Carvykti and Darzalex Faspro in Multiple Myeloma Trials

J&J announced positive clinical trial data for its multiple myeloma drugs Carvykti and Darzalex Faspro, showing improved outcomes. Carvykti demonstrated a 45% reduction in death risk and 76% OS rate at 30 months, while Darzalex Faspro improved minimal residual disease-negativity by 60.9%.
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy